Primary Bioscience, Inc

Primary Bioscience, Inc, based in Seattle, US, focuses on advanced protein sequencing technology, enabling precise biomarker screening for research and clinical applications. Founded in 2023, Primary Bioscience, Inc specializes in protein sequencing technology. The company was established as an independent entity, aiming to address the limitations in biomarker detection and analysis. Its headquarters is located in Seattle, US.

The recent funding round occurred in September 2025, marking its ongoing efforts to innovate in the biotech space. No information is available regarding previous endeavors of the founder. Primary Bioscience specializes in developing a single molecule protein sequencing device that supports comprehensive multi-biomarker screening. This innovative product facilitates unbiased protein sequencing within samples, identifying complex variations such as single residue substitutions, splice variants, and post-translational modifications.

Its clientele includes research institutions, clinical laboratories, and pharmaceutical companies, all utilizing the technology to enhance biomarker discovery and therapeutic development. The company's products are primarily marketed in North America and Europe, focusing on regions with demand for precision proteomics and personalized medicine solutions. Primary Bioscience generates revenue through direct sales of its proprietary protein sequencing device and associated services. The company engages in B2B transactions with academic institutions and biotech firms requiring high-throughput protein analysis.

Transactions typically include device sales alongside service agreements for support and maintenance. Additionally, subscription models may be offered for software updates and data analysis support, catering to varying customer needs while maintaining competitive market positioning. In September 2025, Primary Bioscience raised an undisclosed amount of Seed funding from SOSV to support its expansion initiatives. The company plans to develop new products aimed at enhancing its sequencing capabilities, targeting launch within the next two years.

Primary Bioscience also aims to expand its market presence in Europe and Asia by 2026, leveraging its recent funding to enhance research and development efforts, improving its technology and customer engagement.